The U.S. Food and Drug Administration (FDA) has approved a new treatment for agitation in Alzheimer’s patients, marking a significant step forward in managing this challenging aspect of the disease. The drug, called Auvelity, was initially approved in 2022 for treating major depressive disorder in adults but has now been recognized for its effectiveness in addressing agitation related to dementia.
Agitation is a frequent and distressing symptom experienced by many people with Alzheimer’s. It can manifest as excessive movement or aggressive behavior, which can be difficult for both patients and their caregivers. The FDA emphasized that managing agitation is crucial, as it greatly affects the quality of life for everyone involved.
In a recent announcement, the FDA commissioner highlighted that this approval is an important milestone for families dealing with Alzheimer’s. This new option gives hope to patients struggling with the complexities of the disease.
Auvelity has shown promising results in two studies. In the first trial, caregivers reported on the frequency of agitated behaviors in patients treated with Auvelity over five weeks. The results indicated that the drug produced significantly better outcomes than a placebo. The second study investigated how long the positive effects of the medication lasted after treatment was stopped, finding that patients who continued taking Auvelity experienced more prolonged relief from agitation.
Auvelity comes in fast-acting extended-release tablets, and health providers are advised to closely monitor patients’ blood pressure and assess their medical history, especially concerning bipolar disorder and other medications, before prescribing it.
While the drug offers new hope, it can also lead to some side effects. Common issues include dizziness, upset stomach, headaches, and drowsiness, among others. There’s also a risk of more severe side effects, such as seizures and increased blood pressure, particularly at higher doses. Additionally, healthcare providers must keep an eye out for signs of suicidal thoughts in younger adults when using this medication.
Dr. Marc Siegel, a senior medical analyst, supported the FDA’s decision, stating that Auvelity targets specific brain receptors to help reduce both agitation and depression in older adults with dementia. He noted that it may be a better alternative to traditional antipsychotics due to fewer side effects, making it easier on the heart for older patients.
The approval of Auvelity provides both patients and caregivers with a valuable new tool in the ongoing fight against the challenges of Alzheimer’s disease, offering hope for improved care and quality of life.
